From February 1989 to August 1992, 26 patients who presented with an initial pathological diagnosis of glioblastoma multiforme underwent tumor debulking (17) or biopsy (9), stereotactic radiosurgery (SR) and standard radiation therapy (dose range 50–66 Gy) as part of their primary tumor therapy. Presenting characteristics included median age of 55 years (range 20–79), Karnofsky Performance Score (KPS) median 82.5 (20–100), and median tumor volume 18.6 cm3 (2.2–58,7). SR collimator size ranged from 2.25 to 4 cm with a central dose of 15–35 Gy. Isocenter location, collimator size and beam paths were individualized using three-dimensional software such that the maximum possible solid angle was subtended without exceeding a 20% tumor dose gradient. The mean follow-up was 10.9 months (6–19.5) with a median of 9.5 months. Statistical analysis was performed using Kaplan-Meier actuarial analysis developing predicted 12-month survival rates. There were no significant differences noted in patient survival for the parameters of biopsy versus debulking, single versus multiple isocenters, age, initial KPS, and patterns of steroid requirement. Radiographic recurrences were divided by location into central (within central SR dose) = 0, peripheral (within 1 cm of central dose) = 16, and distant (<1 cm) = 4. Predicted 12-month survival was 24%, with a median survival of 9.5 months. These values are similar to previous results for surgery and standard radiotherapy alone [1]. The results suggest that radiosurgery, when used as a mode of primary therapy, offers little or no benefit in quality of life or survival as recurrences occur immediately outside or distant to the central SR field.

Keywords:
Radiosurgery, Stereotactic surgery, Brain tumor, Glioblastoma
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.